Semaglutide ભારતમાં: સંપૂર્ણ દર્દી માર્ગદર્શિકા
Semaglutide ભારતમાં રક્ત શર્કરા અને વજ़ન દોનોં માટે સબસે ચર્ચિત GLP-1 RA મેં—diabetologist સે યા generic market સે. Drug class (brand નહીં) સમઝના informed decisions માં મદદ. Forms, dosing, cost, safety, CDSCO/RSSDI/ICMR—2026 generic, oral vs injectable, Schedule H budgeting.
Short answer
Semaglutide સાપ્તાહિક/દૈનિક GLP-1 RA હૈ, ICMR/RSSDI કે અનુસાર T2D અને BMI ≥27.5 યા ≥25 સહ-રોગ obesity માટે. પ્રિસ્ક્રિપ્શન, titration, CDSCO sourcing. માસિક ₹8,000–₹20,000, generic સસ્તા. Oral/injectable અલગ timing/storage. Kesho શિક્ષણ—પ્રિસ્ક્રાઇબ/બેચતે નહીં.
Key takeaways
- •Semaglutide GLP-1 RA—દવા વર્ગ કા અણુ—lifestyle product નહીં; CDSCO approval અને Schedule H prescription અનિવાર્ય.
- •ભારતમાં weekly injection અને daily oral દોનોં ઉપલબ્ધ; પ્રત્યેક કી timing, storage, titration અલગ.
- •RSSDI metformin/lifestyle અપર્યાપ્ત હો તો semaglutide સહિત GLP-1 RA—CVD/obesity comorbidity પર વિશેષ.
- •CDSCO-approved generic semaglutide 20–40% લાગત કમ, ફક્ત licensed pharmacy valid prescription safe.
- •Titration માં મચકોડ expected; escalation ધીમી, Indian meal patterns adjust—weeks માં tolerance.
- •Long-term: pharmacotherapy + medical nutrition therapy, quarterly follow-up, CDSCO-approved licensed pharmacy only.
Semaglutide શું હૈ?
Semaglutide GLP-1 RA—gut hormone GLP-1 mimic: insulin release, glucagon કમ, stomach emptying ધીમા, appetite કમ. Drug class, single brand નહીં. CDSCO T2D અને selected obesity BMI/comorbidity ICMR/RSSDI. SUSTAIN, STEP meaningful HbA1c/weight lifestyle કે સાથ. Schedule H prescription-only. Kesho prescribe/sell નહીં—education. Prescription specific CDSCO product, principles class mechanism. Generic market molecule packaging સે અધિક important.
Semaglutide
Long-acting GLP-1 RA weekly injection યા daily oral—T2D/obesity medical supervision.
ભારતમાં semaglutide કૌન-સે forms?
Subcutaneous weekly pens low dose gradual weeks—dose titration nausea કમ. Oral daily empty stomach, 30 min before food. CDSCO, prescription. Generic lower price post-patent. Packaging manufacturer, batch, expiry verify. Pens 2–8°C; after <30°C weeks. Oral strict morning—empty-stomach skip absorption કમ.
ભારતમાં semaglutide કિસે લાભ?
T2D: RSSDI metformin/lifestyle insufficient, CVD, obesity, hypoglycaemia. Weight: BMI ≥27.5 યા ≥25 comorbidity ICMR. Thin-fat modest BMI risk—waist, visceral fat. Thyroid, pancreatitis, kidney, pregnancy, interactions assess. T1D/DKA નહીં. CVD outcome benefit individualised.
Semaglutide dosing/titration કેવી રીતે?
Doctor gradual escalation. Weekly 0.25 mg 4 weeks → 0.5, 1 mg+. Oral 3→7→14 mg. Skip/self-adjust = nausea, vomiting, stop risk. GI 4–8 weeks peak then adapt. Same weekly day, rotate sites. Missed >5 days skip—double નહીં. Festival: reminders, travel storage.
Semaglutide formulations એક નજ़ર
- વિશેષતા: Frequency — Weekly injection: સાપ્તાહિક — Oral: દૈનિક
- વિશેષતા: Administration — Weekly: Subcutaneous pen — Oral: ખાલી પેટ, 30 min પહલે
- વિશેષતા: Titration — Weekly: 0.25 → 0.5 → 1 mg+ — Oral: 3 → 7 → 14 mg
- વિશેષતા: Storage — Weekly: Refrigerate — Oral: Room temp label
- વિશેષતા: Trade-off — Weekly: Needle; trial data — Oral: Strict timing; 30 min no food
2026 ભારત semaglutide cost?
City/pharmacy/dose/innovator-generic vary. Injectable ₹8,000–₹20,000/month. CDSCO generic licensed only. Social-media/compounded advisories. Insurance obesity rare. Cost early discuss—stop without lifestyle regain. Tier-2 metro compare GST. Titration lower dose one pen at a time.
Registered practitioner valid prescription બિના semaglutide never purchase. Unapproved counterfeit/degraded/wrong dose risk.
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026